Omeros Corporation (OMER) and Tenax Therapeutics (TENX): 2 Undervalued Biotechs

By Jorge Aura  - November 3, 2017

The biopharmaceutical sector is living a speculation moment. The general feeling among investors is that great advances with the fight against cancer are going to be produced and the existing medication will be improved. Some companies conduct promising studies against cancer. It is speculated that before 10 years we could have a substantial improvement in the partial cure of the most deadly cancers. Meanwhile, other companies are trying to improve the current medication for the orphan indications and critical care market.

There are three companies that are making some spectacular progress in their studies. Omeros Corporation (NASDAQ:OMER) and Tenax Therapeutics Inc (TENX).

In the next article I will write about the reasons to take a speculative position in these companies.

1. Omeros Corporation

According google finance, Omeros Corporation is a biopharmaceutical company that is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery. (Source: Google finance).

Pipeline Portfolio

(Source: Omeros Corporation)

Next Catalyst

-  Phase 3 program for OMS721 in patients with IgA nephropathy.
-  Revenues about OMIDRIA^® in last quarter financials.

Fundamentals Analysis 

Short interest

(SOURCE)

Analyst Research


(SOURCE)

Financials

The company reported the second-quarter financial results on August 8 with the following highlights:

Revenue	$17.2MM
Net Income	($14.4MM)
Cash	$29.7MM

Chart Analysis

- Rsi marks an oversold. The MACD marks a possible change in upward trend.

2. Tenax Therapeutics Inc

According google finance, Tenax Therapeutics is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect. (Source: Google finance).

Pipeline Portfolio

 (Source: Tenax Therapeutics inc)

Next Catalyst

- LEVO-CTS confirmatory trial in cardiac surger.
- NDA news about LEVO-CTS.
- Possible partners or collaborations.

Fundamentals Analysis 

Short interest

(SOURCE)

Analyst Research

(SOURCE)

Financials

The company reported the second-quarter financial results on August 9 with the following highlights:

Revenue	$0MM
Net Income	($2.98MM)
Cash	$8.99MM

Chart Analysis

- The MACD marks a possible change in upward trend.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Read More

Biopharma stocks: 3 Undervalued Small-caps

By Jorge Aura

All investors know the risks of biotechnology companies. The strong volatility of these companies makes their prices fluctuate in excess. This sector has the peculiarity that offers a high risk but with a possible high gain. Identify pharmaceutical companies that have bottomed out or that are undervalued can be a good investment strategy for medium-term and short-term. In the following table will be able to see the readers, 3 companies which have greatly reduced their quoted prices since on January 6, 2017.

Company	January 6, 2017	July 7, 2017
Galena Biopharma Inc	$2.07	$0.55
Repros Therapeutics Inc	$1.36	$0.50
Navidea Biopharmaceuticals Inc	$0.625	$0.49

As you have seen in the upper table these companies have been hit hard during July, 2017. To determine if these companies are undervalued I have made a fundamental analysis of each company.

Galena Biopharma Inc (NASDAQ: GALE) is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets.
Source: Google finance

Galena lead product candidate is GALE-401. This product contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms ("MPNs") to lower abnormally elevated platelet levels. The currently available immediate release ("IR") version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent, and may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration ("Cmax") and increasing the half-life of the drug is hypothesized to reduce the side effects, while preserving the efficacy, potentially allowing a broader use of the drug.
Source: Galena Biopharma Inc

Galena Biopharma has a market cap of $21.18 million. Its trailing P/E is 2.51. It has a total cash position on its balance sheet of just $42.046,Million. The company announced a revenue on three months ended March 31 of $0.


             Source: Stockcharts.com

This stock plunged from its high of $4.75 to a recent low of $0.16. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.58 a share. Look for volume that's tracking in close to or above its three-month average action of 599,062 shares. Keep in mind that the company has approved the possibility of performing a reverse split recently.

Repros Therapeutics Inc (NASDAQ: RPRX) is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Source: Google finance

Repros Therapeutics has a market cap of $16.98 million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization.  It has a total cash position on its balance sheet of just $3.23 Million. The company announced a revenue on three months ended March 31 of $0.

           Source: Stockcharts.com

This stock plunged from its high of $2.48 to a recent low of $0.33. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.58 a share. Look for volume that's tracking in close to or above its three-month average action of 905,240 shares.

Navidea Biopharmaceuticals Inc (NYSEAMEX: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Source: Google finance

Navidea has a market cap of $78.10 Million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $13.44 Million. The company announced a revenue on three months ended March 31 of $580,000.

           Source: Stockcharts.com

This stock plunged from its high of $1.16 to a recent low of $0.26. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.50 a share. Look for volume that's tracking in close to or above its three-month average action of 386,176 shares.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Read More

3 Reasons to Buy Tenax Therapeutics, Inc

By Jorge Aura

Tenax Therapeutics, Inc (NASDAQ: TENX) According Google Finance, Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Pipeline Overview:

 Source: Tenax Therapeutics Inc

Fundamental Basic Review

Tenax Therapeutics Inc has a market cap of $15,35 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $19,15 million, and its total debt is at $0. In Tenax therapeutics last quarter, we can see that its operating expenses reached $3,48 million. Based on the operating expenses and the company's cash deducting the current debt from them, we can think that the company would have enough cash for the next four financial quarters or second quarter of 2018.

I find at least four reasons to buy the stock currently:

1.  Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission

On May 16, 2017 Tenax Therapeutics announced to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission.

Tenax met with the FDA on May 10, 2017 to review additional data analyses from the recently completed Phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at risk of LCOS. The discussion with the FDA built on previously presented primary data analyses of the LEVO-CTS trial that identified a significant interaction in levosimendan’s effectiveness across surgery types enrolled in the study.

Levosimendan NDA Submission is a big potential catalyst for the next weeks.

2. Analysts' price target: $4

  

 Source: Nasdaq.com

- On May 18, 2017 Ladenburg Thalmann Upgrades From Neutral to Buy Tenax Therapeutics. The price target market was $2.5 per share.

Analyst Jeffrey Cohen of Ladenburg Thalmann said:

"On May 16th Tenax announced that they had met with the FDA on May 10th to discuss subgroup analysis of the previously announced topline data from their Phase III LEVOCTS Trial. Isolated Coronary Artery Bypass Grafting (CABG) was the largest of the three trial subgroups (563/849 or 66.3%) with the other two being valve replacement with CABG or Valve replacement alone. Yesterday, the company added a new corporate presentation to their website which we believe offers a significant body of evidence related to levosimendan (Simdax) and its effect upon cardiac surgery isolated for CABG.

 Cohen believes that the company will submit additional information from published studies not included in meeting background document within the next 2-6 weeks with expected FDA feedback concerning a filing in July/August. If positive, they would anticipate a filing during Q3-2017."

3. Institutional ownership: 10,51%

- Sabby Capital LLC own 1,16 MM shares .

Source: Nasdaq.com



Conclusion:
Tenax Therapeutics is a  tremendously undervalued company. It has a capitalization of $15,35MM and a cash flow of $19,15MM. Levosimendan treatment can provide it with an income of $300MM annually minimum. This enterprise should have a minimum capitalization of $150MM or $5 per share.

*Pipeline overview data sourced from Tenax Therapeutics, Inc, all other data sourced from Nasdaq.com, as well as the web of the previously mentioned company.

Disclosure: Jorge Aura owns shares of Tenax Therapeutics Inc, Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Read More